- Home
- EVAX vs AQMS Comparison
EVAX vs AQMS Comparison
Compare EVAX & AQMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVAX
- AQMS
- Stock Information
- Founded
- EVAX 2008
- AQMS 2014
- Country
- EVAX Denmark
- AQMS United States
- Employees
- EVAX N/A
- AQMS N/A
- Industry
- EVAX Biotechnology: Biological Products (No Diagnostic Substances)
- AQMS Metal Fabrications
- Sector
- EVAX Health Care
- AQMS Industrials
- Exchange
- EVAX Nasdaq
- AQMS Nasdaq
- Market Cap
- EVAX 16.3M
- AQMS 13.7M
- IPO Year
- EVAX 2021
- AQMS 2015
- Fundamental
- Price
- EVAX $1.69
- AQMS $1.76
- Analyst Decision
- EVAX Strong Buy
- AQMS Strong Buy
- Analyst Count
- EVAX 2
- AQMS 3
- Target Price
- EVAX $10.00
- AQMS $21.00
- AVG Volume (30 Days)
- EVAX 65.8K
- AQMS 48.2K
- Earning Date
- EVAX 05-27-2025
- AQMS 05-14-2025
- Dividend Yield
- EVAX N/A
- AQMS N/A
- EPS Growth
- EVAX N/A
- AQMS N/A
- EPS
- EVAX N/A
- AQMS N/A
- Revenue
- EVAX $3,344,000.00
- AQMS N/A
- Revenue This Year
- EVAX $102.45
- AQMS N/A
- Revenue Next Year
- EVAX $200.44
- AQMS $550.00
- P/E Ratio
- EVAX N/A
- AQMS N/A
- Revenue Growth
- EVAX 4480.82
- AQMS N/A
- 52 Week Low
- EVAX $1.61
- AQMS $1.33
- 52 Week High
- EVAX $22.05
- AQMS $13.78
- Technical
- Relative Strength Index (RSI)
- EVAX 36.47
- AQMS 40.07
- Support Level
- EVAX $1.67
- AQMS $1.89
- Resistance Level
- EVAX $1.97
- AQMS $2.10
- Average True Range (ATR)
- EVAX 0.12
- AQMS 0.16
- MACD
- EVAX 0.04
- AQMS -0.02
- Stochastic Oscillator
- EVAX 22.22
- AQMS 4.64
About EVAX Evaxion Biotech
Evaxion Biotech AS is a clinical-stage biotech company that aspires to the exploration of artificial intelligence, or AI, to develop immunotherapies with improved efficacy when compared to currently marketed products for patients with unmet medical needs. Its pipeline programs are derived from its proprietary AI platforms, PIONEER, EDEN, RAVEN, and ObsERV. The company is utilizing these AI platforms to build a drug development pipeline. Its product candidates are; EVX-01 and EVX-02, for the treatment of various cancers, and the third candidate is cancer immunotherapy, EVX-03, for the treatment of various cancers including non-small-cell-lung-cancer, or NSCLC, is in pre-clinical development.
About AQMS Aqua Metals Inc.
Aqua Metals Inc is engaged in the business of recycling Lead through a novel, proprietary and patent-pending process that it developed and named AquaRefining. The company's breakthrough, AquaRefining, delivers a product, at a higher yield, eliminates toxic waste, reduces permitting and is less expensive to build than smelting. AquaRefining process will provide for the recycling of Lead acid batteries and the production of a pure grade Lead with a significantly lower cost of production, and with fewer environmental and regulatory issues, than conventional methods of Lead production.